These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 1443052)

  • 1. Anthracyclines selectively decrease alpha cardiac actin mRNA abundance in the rat heart.
    Papoian T; Lewis W
    Am J Pathol; 1992 Nov; 141(5):1187-95. PubMed ID: 1443052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adriamycin cardiotoxicity in vivo. Selective alterations in rat cardiac mRNAs.
    Papoian T; Lewis W
    Am J Pathol; 1990 Jun; 136(6):1201-7. PubMed ID: 2356854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity.
    Sawyer DB; Zuppinger C; Miller TA; Eppenberger HM; Suter TM
    Circulation; 2002 Apr; 105(13):1551-4. PubMed ID: 11927521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Actin isoform mRNA alterations induced by doxorubicin in cultured heart cells.
    Lewis W; Gonzalez B
    Lab Invest; 1990 Jan; 62(1):69-76. PubMed ID: 2296159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro.
    Ito H; Miller SC; Billingham ME; Akimoto H; Torti SV; Wade R; Gahlmann R; Lyons G; Kedes L; Torti FM
    Proc Natl Acad Sci U S A; 1990 Jun; 87(11):4275-9. PubMed ID: 2349236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective alterations in rat cardiac mRNA induced by doxorubicin: possible subcellular mechanisms.
    Papoian T; Lewis W
    Exp Mol Pathol; 1991 Apr; 54(2):112-21. PubMed ID: 1709408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anthracyclines enhance tension development in cardiac muscle by direct interaction with the contractile system.
    Bottone AE; de Beer EL; Voest EE
    J Mol Cell Cardiol; 1997 Mar; 29(3):1001-8. PubMed ID: 9152861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistent effects of doxorubicin on cardiac gene expression.
    Boucek RJ; Miracle A; Anderson M; Engelman R; Atkinson J; Dodd DA
    J Mol Cell Cardiol; 1999 Aug; 31(8):1435-46. PubMed ID: 10423342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of cardiac pathology in relation to anthracycline cardiotoxicity.
    Ferrans VJ
    Cancer Treat Rep; 1978 Jun; 62(6):955-61. PubMed ID: 352510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking.
    Xu X; Sutak R; Richardson DR
    Mol Pharmacol; 2008 Mar; 73(3):833-44. PubMed ID: 18029550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of mRNA levels by the polymerase chain reaction in small cardiac tissue samples.
    Ito H; Miller SC; Akimoto H; Torti SV; Taylor A; Billingham ME; Torti FM
    J Mol Cell Cardiol; 1991 Oct; 23(10):1117-25. PubMed ID: 1749003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of doxorubicin, 4'-epirubicin, and antioxidant enzymes on the contractility of isolated cardiomyocytes.
    Chan EM; Thomas MJ; Bandy B; Tibbits GF
    Can J Physiol Pharmacol; 1996 Aug; 74(8):904-10. PubMed ID: 8960379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel cardiac-restricted target for doxorubicin. CARP, a nuclear modulator of gene expression in cardiac progenitor cells and cardiomyocytes.
    Jeyaseelan R; Poizat C; Baker RK; Abdishoo S; Isterabadi LB; Lyons GE; Kedes L
    J Biol Chem; 1997 Sep; 272(36):22800-8. PubMed ID: 9278441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different cytotoxicity and metabolism of doxorubicin, daunorubicin, epirubicin, esorubicin and idarubicin in cultured human and rat hepatocytes.
    Le Bot MA; Bégué JM; Kernaleguen D; Robert J; Ratanasavanh D; Airiau J; Riché C; Guillouzo A
    Biochem Pharmacol; 1988 Oct; 37(20):3877-87. PubMed ID: 3190734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of cardiac guanylate cyclase by doxorubicin and some of its analogs: possible relationship to cardiotoxicity.
    Lehotay DC; Levey BA; Rogerson BJ; Levey GS
    Cancer Treat Rep; 1982 Feb; 66(2):311-6. PubMed ID: 6120040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha-actin synthesis changes in cultured cardiac myocytes: relationship to anthracycline structure.
    Lewis W; Perillo NL; Gonzalez B
    J Lab Clin Med; 1988 Jul; 112(1):43-51. PubMed ID: 3164748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anthracycline effects on actin and actin-containing thin filaments in cultured neonatal rat myocardial cells.
    Lewis W; Gonzalez B
    Lab Invest; 1986 Apr; 54(4):416-23. PubMed ID: 3959544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of exogenous melatonin in reducing the cardiotoxic effect of daunorubicin and doxorubicin in the rat.
    Dziegiel P; Jethon Z; Suder E; Sopel M; Rabczyński J; Surowiak P; Zabel M
    Exp Toxicol Pathol; 2002 Feb; 53(6):433-9. PubMed ID: 11926284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha 1-adrenergic receptor stimulation of sarcomeric actin isogene transcription in hypertrophy of cultured rat heart muscle cells.
    Long CS; Ordahl CP; Simpson PC
    J Clin Invest; 1989 Mar; 83(3):1078-82. PubMed ID: 2537847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of oxygen uptake in vitro as an index of cardiac toxicity induced by new anthracyclines.
    Cini-Neri G; Neri B
    Anticancer Res; 1986; 6(2):195-7. PubMed ID: 3458425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.